Seroquel Evaluation On Improvement In Short And Long-Term Symptoms June 18, 2009
AstraZeneca (NYSE:AZN) announced new study data on SEROQUEL XR™ (quetiapine fumarate) Extended-Release Tablets (quetiapine XR) for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adult patients. The results from the studies were presented today at the 161st Annual Meeting of the American Psychiatric Association (APA) in Washington, DC. In [...]
